A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

What Was Tested

In this phase 3 trial, researchers set out to test Ecnoglutide.

It had two arms (groups): Ecnoglutide Injection (experimental) and Placebo (placebo comparator).

Once weekly.

Once weekly.

The registry classes the interventions as drug.

More on the Plan

The overall study will last for 73 weeks.

Who Took Part

The registry lists 360 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Body mass index (BMI) ≥ 28.0 kg/m\^2;. Self-reported by the participant who has a history of unsuccessful weight loss attempt by diet and exercise.

The full record lists 5 inclusion and 14 exclusion criteria; among the exclusions: the target knee has undergone joint replacement surgery;; the target knee has undergone arthroscopy within 12 months prior to screening;; history of joint instability in either knee within 12 months prior to screening, such as anterior cruciate ligament rupture or recent trauma;.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Ecnoglutide and who got the comparison, which limits bias.

The Ecnoglutide group and the comparison group ran side by side rather than switching.

As a double-blind Ecnoglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2026-08-03 with completion listed for 2028-05-31.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score (time frame: Baseline, week 68). Percentage Change in Body Weight (time frame: Baseline, week 68).

It also tracked 32 secondary outcomes, for example Change in WOMAC Physical Function Subscale Score, Change in Short Form 36 (SF36) V2 Physical Function Subscale Score, Absolute Change in Body Weight, Change in WOMAC Total Score, Change in SF36V2 Score and Change in PGI-S Pain and Function Score of the Target Knee Joint.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Ecnoglutide in 360 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Ecnoglutide compound page, all human trials.